Results 81 to 90 of about 311,527 (352)

Safety and patient satisfaction of abobotulinumtoxinA for aesthetic use. A systematic review [PDF]

open access: yes, 2017
A systematic review of the published literature (from January 2000 to January 2016) to ascertain the safety of, and patient satisfaction with, the aesthetic use of abobotulinumtoxinA was conducted.
Cohen, Joel L, Scuderi, Nicolo'
core   +1 more source

Botulinum toxin and spasticity [PDF]

open access: yesJournal of Neurology, Neurosurgery & Psychiatry, 2000
The clinical effects of botulinum toxin have been recognised since the end of the 19th century. It is the most potent neurotoxin known and it is produced by the gram negative anaerobic bacterium Clostridium botulinum. The paralytic effect of the toxin is due to blockade of neuromuscular transmission.1 Injection into a muscle causes chemodenervation and
Michael P Barnes, Elizabeth C. Davis
openaire   +2 more sources

Operating Room or In‐Office Injection for Retrograde Cricopharyngeal Dysfunction Botulinum Toxin Injection

open access: yesThe Laryngoscope, EarlyView.
ABSTRACT Background Retrograde Cricopharyngeal Dysfunction (RCPD), also known as “No Burp Syndrome,” is a rare condition characterized by the inability to burp due to cricopharyngeus muscle dysfunction. Patients experience bloating, chest and abdominal discomfort, gurgling sounds, and excessive flatulence, which significantly impact quality of life ...
Salwa AlRashed AlHumaid   +2 more
wiley   +1 more source

Postoperative Fluoroscopic Appearance After Flexible Endoscopic Zenker's Diverticulotomy

open access: yesThe Laryngoscope, EarlyView.
We perform a retrospective study on patients undergoing flexible Zenker's diverticulotomy surgery and report changes in the objective fluoroscopic appearance as well as patient‐reported outcome measures. ABSTRACT Objective Flexible approach to treating Zenker's diverticulum (ZD) has gained traction in recent years. However, objective measures comparing
Shumon I. Dhar   +7 more
wiley   +1 more source

Botulinum toxin type A in chronic neuropathic pain in refractory leprosy

open access: yesArquivos de Neuro-Psiquiatria
Neuropathic pain is a chronic syndrome that is difficult to treat and often affects patients with leprosy. Recommended treatment includes the the use of analgesic drugs, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide ...
Emanuel de Jesus Soares de Sousa   +4 more
doaj   +1 more source

Cost-Effectiveness of Treating Upper Limb Spasticity Due to Stroke with Botulinum Toxin Type A: Results from the Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial [PDF]

open access: yes, 2012
Stroke imposes significant burdens on health services and society, and as such there is a growing need to assess the cost-effectiveness of stroke treatment to ensure maximum benefit is derived from limited resources.
Christopher Price   +16 more
core   +3 more sources

Hazard analysis and possibilities for preventing botulism originating from meat products [PDF]

open access: yesVeterinarski Glasnik, 2008
The paper presents the more important data on the bacteria Clostridium botulinum, the appearance of botulism, hazard analysis and the possibilities for preventing botulism.
Vasilev Dragan, Vuković Ilija
doaj   +1 more source

Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination Against Botulinum C and D Neurotoxins. [PDF]

open access: yes, 2019
Botulism is caused by botulinum neurotoxin (BoNT), the most poisonous substance known. BoNTs are also classified as Tier 1 biothreat agents due to their high potency and lethality.
Cobb, Ronald R   +12 more
core  

Botulinum toxin-A for the treatment of overactive bladder: UK contributions [PDF]

open access: yes, 2013
Background: Botulinum toxin-A (BoNT/A) is now established second-line management for refractory overactivebladder (OAB) and recognised in many incontinence guidelines and pathways.
Dasgupta, P   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy